Aileron Therapeutics Inc (ALRN)

$2.74

-0.06

(-2.14%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $2.70
    $3.00
    $2.74
    downward going graph

    1.46%

    Downside

    Day's Volatility :10.0%

    Upside

    8.67%

    downward going graph
  • $1.01
    $7.42
    $2.74
    downward going graph

    63.14%

    Downside

    52 Weeks Volatility :86.39%

    Upside

    63.07%

    downward going graph

Returns

PeriodAileron Therapeutics IncIndex (Russel 2000)
3 Months
-42.32%
0.0%
6 Months
-32.68%
0.0%
1 Year
55.24%
0.0%
3 Years
-87.08%
-19.4%

Highlights

Market Capitalization
58.8M
Book Value
$2.66
Earnings Per Share (EPS)
-3.23
PEG Ratio
0.0
Wall Street Target Price
13.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-19.94%
Return On Equity TTM
-34.21%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-17.0M
EBITDA
-18.4M
Diluted Eps TTM
-3.23
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.13
EPS Estimate Next Year
-1.78
EPS Estimate Current Quarter
-0.14
EPS Estimate Next Quarter
-0.16

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Aileron Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
00
00
Hold
1
3
3
Sell
00
3
3

Analyst Forecast

What analysts predicted

Upside of 374.45%

Current $2.74
Target $13.00

Technicals Summary

Sell

Neutral

Buy

Aileron Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aileron Therapeutics Inc
Aileron Therapeutics Inc
-9.87%
-32.68%
55.24%
-87.08%
-72.97%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aileron Therapeutics Inc
Aileron Therapeutics Inc
NA
NA
0.0
-2.13
-0.34
-0.2
NA
2.66
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aileron Therapeutics Inc
Aileron Therapeutics Inc
Buy
$58.8M
-72.97%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Aileron Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 59.9% return, outperforming this stock by 4.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 200.6% return, outperforming this stock by 287.7%

Institutional Holdings

  • SATTER MANAGEMENT CO., L.P.

    3.85%
  • Nantahala Capital Management, LLC

    1.18%
  • RIMA MANAGEMENT, LLC

    1.07%
  • Geode Capital Management, LLC

    0.32%
  • Sigma Planning Corp

    0.31%
  • Renaissance Technologies Corp

    0.21%

Company Information

aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig

Organization
Aileron Therapeutics Inc
Employees
15
CEO
Dr. James Brian Windsor Ph.D.
Industry
Health Technology

FAQs